Fig. 4: Association between cardiovascular-kidney-metabolic syndrome stages and all-cause/cardiovascular mortality in the Kailuan cohort. | Communications Medicine

Fig. 4: Association between cardiovascular-kidney-metabolic syndrome stages and all-cause/cardiovascular mortality in the Kailuan cohort.

From: Cardiovascular-kidney-metabolic (CKM) syndrome is associated with increased mortality in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD)

Fig. 4

A All-cause mortality; B Cardiovascular mortality; (a) Overall cohort; (b) Patients aged <60 years; (c) Patients aged ≥60 years. Note: Hazard ratios were estimated using Cox proportional hazards regression models (two-sided tests). No adjustments were made for multiple comparisons. Multivariable model: adjusted for sex and age (not adjusted for age subgroup); adjusted for IPTW: the multivariable model was adjusted after IPTW. The central marker represents the hazard ratio (point estimate), and the error bars indicate the 95% confidence intervals. A (a): total number, n = 22,865; stage 1, n = 3366; stage 2, n = 18,074; stages 3 and 4, n = 1425. A (b): total number, n = 17,832; stage 1, n = 2982; stage 2, n = 14,074; stages 3 and 4, n = 776. A (c): total number, n = 5033; stage 1, n = 384; stage 2, n = 4000; stages 3 and 4, n = 649. B (a): total number, n = 20,164; stage 1, n = 2822; stage 2, n = 15,098; stages 3 and 4, n = 2244. B (b): total number, n = 15,712; stage 1, n = 2627; stage 2, n = 12,400; stage 3–4, n = 685. B (c): total number, n = 4452; stage 1, n = 339; stage 2, n = 3,538; stage 3–4, n = 575. PTW inverse probability of treatment weighting, HR Hazard ratio, 95% CI 95% confidence interval.

Back to article page